Bridgewater Associates LP Sells 860 Shares of Glaukos Co. (NYSE:GKOS)

Bridgewater Associates LP cut its holdings in Glaukos Co. (NYSE:GKOS) by 9.3% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 8,374 shares of the medical instruments supplier’s stock after selling 860 shares during the quarter. Bridgewater Associates LP’s holdings in Glaukos were worth $1,091,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Cetera Advisors LLC acquired a new position in shares of Glaukos during the 1st quarter valued at $213,000. GAMMA Investing LLC grew its holdings in Glaukos by 68.8% in the second quarter. GAMMA Investing LLC now owns 1,192 shares of the medical instruments supplier’s stock worth $141,000 after purchasing an additional 486 shares during the period. LVW Advisors LLC acquired a new stake in Glaukos in the second quarter worth $213,000. Sequoia Financial Advisors LLC acquired a new stake in Glaukos in the second quarter worth $229,000. Finally, Assenagon Asset Management S.A. acquired a new stake in Glaukos in the second quarter worth $6,832,000. 99.04% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms have commented on GKOS. StockNews.com upgraded shares of Glaukos from a “sell” rating to a “hold” rating in a report on Monday, October 21st. JPMorgan Chase & Co. raised their price target on shares of Glaukos from $130.00 to $145.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. Wells Fargo & Company raised their price target on shares of Glaukos from $135.00 to $145.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. BTIG Research lifted their price objective on shares of Glaukos from $140.00 to $149.00 and gave the company a “buy” rating in a report on Tuesday, November 26th. Finally, Stifel Nicolaus lifted their price objective on shares of Glaukos from $130.00 to $145.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $135.45.

Insider Activity at Glaukos

In other Glaukos news, Director Gilbert H. Kliman sold 3,000 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $130.67, for a total transaction of $392,010.00. Following the sale, the director now directly owns 32,336 shares of the company’s stock, valued at $4,225,345.12. This represents a 8.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Joseph E. Gilliam sold 2,275 shares of the company’s stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $138.97, for a total transaction of $316,156.75. Following the sale, the chief operating officer now directly owns 102,169 shares in the company, valued at approximately $14,198,425.93. This trade represents a 2.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.40% of the stock is owned by company insiders.

Glaukos Stock Performance

NYSE GKOS opened at $143.65 on Monday. Glaukos Co. has a 1 year low of $59.58 and a 1 year high of $146.86. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71. The firm has a market cap of $7.92 billion, a price-to-earnings ratio of -47.57 and a beta of 1.02. The company has a fifty day moving average price of $134.13 and a 200-day moving average price of $124.96.

Glaukos (NYSE:GKOS) last posted its earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.20. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. The firm had revenue of $96.70 million during the quarter, compared to analyst estimates of $91.50 million. During the same quarter in the prior year, the business posted ($0.50) EPS. The business’s revenue was up 23.9% compared to the same quarter last year. As a group, equities research analysts predict that Glaukos Co. will post -1.91 EPS for the current fiscal year.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.